Marquié Marta, Normandin Marc D, Vanderburg Charles R, Costantino Isabel M, Bien Elizabeth A, Rycyna Lisa G, Klunk William E, Mathis Chester A, Ikonomovic Milos D, Debnath Manik L, Vasdev Neil, Dickerson Bradford C, Gomperts Stephen N, Growdon John H, Johnson Keith A, Frosch Matthew P, Hyman Bradley T, Gómez-Isla Teresa
MassGeneral Institute for Neurodegenerative Disease, Charlestown, MA.
Department of Neurology, Massachusetts General Hospital, Boston, MA.
Ann Neurol. 2015 Nov;78(5):787-800. doi: 10.1002/ana.24517. Epub 2015 Sep 25.
To examine region- and substrate-specific autoradiographic and in vitro binding patterns of positron emission tomography tracer [F-18]-AV-1451 (previously known as T807), tailored to allow in vivo detection of paired helical filament-tau-containing lesions, and to determine whether there is off-target binding to other amyloid/non-amyloid proteins.
We applied [F-18]-AV-1451 phosphor screen autoradiography, [F-18]-AV-1451 nuclear emulsion autoradiography, and [H-3]-AV-1451 in vitro binding assays to the study of postmortem samples from patients with a definite pathological diagnosis of Alzheimer disease, frontotemporal lobar degeneration-tau, frontotemporal lobar degeneration-transactive response DNA binding protein 43 (TDP-43), progressive supranuclear palsy, corticobasal degeneration, dementia with Lewy bodies, multiple system atrophy, cerebral amyloid angiopathy and elderly controls free of pathology.
Our data suggest that [F-18]-AV-1451 strongly binds to tau lesions primarily made of paired helical filaments in Alzheimer brains (eg, intraneuronal and extraneuronal tangles and dystrophic neurites), but does not seem to bind to a significant extent to neuronal and glial inclusions mainly composed of straight tau filaments in non-Alzheimer tauopathy brains or to lesions containing β-amyloid, α-synuclein, or TDP-43. [F-18]-AV-1451 off-target binding to neuromelanin- and melanin-containing cells and, to a lesser extent, to brain hemorrhagic lesions was identified.
Our data suggest that [F-18]-AV-1451 holds promise as a surrogate marker for the detection of brain tau pathology in the form of tangles and paired helical filament-tau-containing neurites in Alzheimer brains but also point to its relatively lower affinity for lesions primarily made of straight tau filaments in non-Alzheimer tauopathy cases and to the existence of some [F-18]-AV-1451 off-target binding. These findings provide important insights for interpreting in vivo patterns of [F-18]-AV-1451 retention.
研究正电子发射断层扫描示踪剂[F-18]-AV-1451(以前称为T807)的区域和底物特异性放射自显影及体外结合模式,该示踪剂旨在用于体内检测含双螺旋丝tau蛋白的病变,并确定其是否与其他淀粉样蛋白/非淀粉样蛋白存在脱靶结合。
我们将[F-18]-AV-1451磷屏放射自显影、[F-18]-AV-1451核乳胶放射自显影以及[H-3]-AV-1451体外结合试验应用于确诊为阿尔茨海默病、额颞叶痴呆-tau型、额颞叶痴呆-转录激活反应DNA结合蛋白43(TDP-43)型、进行性核上性麻痹、皮质基底节变性、路易体痴呆、多系统萎缩、脑淀粉样血管病患者的尸检样本以及无病理学病变的老年对照样本的研究。
我们的数据表明,[F-18]-AV-1451与阿尔茨海默病大脑中主要由双螺旋丝构成的tau病变(如神经元内和神经元外缠结以及营养不良性神经突)强烈结合,但在非阿尔茨海默病tau蛋白病大脑中,主要由直tau丝构成的神经元和胶质细胞内含物,或含有β淀粉样蛋白、α突触核蛋白或TDP-43的病变,[F-18]-AV-1451似乎没有明显结合。已确定[F-18]-AV-1451与含神经黑色素和黑色素的细胞存在脱靶结合,且在较小程度上与脑内出血性病变存在脱靶结合。
我们的数据表明,[F-18]-AV-1451有望作为一种替代标志物,用于检测阿尔茨海默病大脑中以缠结和含双螺旋丝tau蛋白的神经突形式存在的脑tau蛋白病变,但也表明其对非阿尔茨海默病tau蛋白病病例中主要由直tau丝构成的病变的亲和力相对较低,且存在一些[F-18]-AV-1451脱靶结合。这些发现为解读[F-18]-AV-1451保留的体内模式提供了重要见解。